Toxin-specific antibodies and antibody fragments for the treatment of Clostridium difficile. Current status and future prospectives

Download
  1. Get@NRC: Toxin-specific antibodies and antibody fragments for the treatment of Clostridium difficile. Current status and future prospectives (Opens in a new window)
DOIResolve DOI: http://doi.org/10.3390/toxins2050998
AuthorSearch for: ; Search for:
TypeArticle
Journal titleToxins
Volume5
Issue2
Pages9981018; # of pages: 21
SubjectClostridium difficile; Clostridium difficile-associated disease; toxin; antibody; single-domain antibody; neutralization; therapy
AbstractTherapeutic agents targeting bacterial virulence factors are gaining interest as non-antibiotic alternatives for the treatment of infectious diseases. Clostridium difficile is a Gram-positive pathogen that produces two primary virulence factors, enterotoxins A and B (TcdA and TcdB), which are responsible for Clostridium difficile-associated disease (CDAD) and are targets for CDAD therapy. Antibodies specific for TcdA and TcdB have been shown to effectively treat CDAD and prevent disease relapse in animal models and in humans. This review summarizes the various toxin-specific antibody formats and strategies under development, and discusses future directions for CDAD immunotherapy, including the use of engineered antibody fragments with robust biophysical properties for systemic and oral delivery.
Publication date
LanguageEnglish
AffiliationNRC Institute for Biological Sciences; National Research Council Canada
Peer reviewedYes
NPARC number17401055
Export citationExport as RIS
Report a correctionReport a correction
Record identifiere619d5d8-6fe6-45e0-a202-030e016ad2c6
Record created2011-03-25
Record modified2016-05-09
Bookmark and share
  • Share this page with Facebook (Opens in a new window)
  • Share this page with Twitter (Opens in a new window)
  • Share this page with Google+ (Opens in a new window)
  • Share this page with Delicious (Opens in a new window)